BioSpace News Archive

Biophytis SA, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, provides updates and perspectives on its Sarconeos programs ahead of its upcoming General Assembly on April 26, 2021.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that its 200 patient ovarian cancer clinical verification study has completed patient enrolment.

GlobalMed, a leading provider of virtual health solutions, announced the successful completion of its SOC 2 Type 2 examination.

AdaptHealth Corp., a national leader in providing patient-centric and technology-enabled chronic disease management solutions including home healthcare equipment, medical supplies to the home and related services in the United States announced that it has amended its senior secured credit facilities to increase its term loan by $100 million and to expand the maximum borrowing capacity under its revolving credit facility from $250 million to $450 million.

100% Renewable Energy Goal to be Achieved 15 Years Ahead of Schedule; Includes Three New Virtual Power Purchase Agreements

Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2021.

Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, announced completion of pre-IND interaction with the U.S. Food and Drug Administration regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies.

Patients Administered ANJESO Prior to the Start of Surgery had Significantly Lower Summed Pain Intensity Scores on the First Postsurgical Day and Throughout Their Inpatient Course

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced positive topline results from its regional multi-center, randomized, double-blind and placebo-controlled phase 2 study

Nephros , Inc. (Nasdaq: NEPH), a leading water technology company, today announced that it will file its first quarter financial results on Thursday, May 6, 2021 after market close and will host a conference call that same day at 4:30 PM ET.